Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access March 30, 2016

Epilobi Hirsuti Herba Extracts Influence the In Vitro Activity of Common Antibiotics on Standard Bacteria

  • Lucia Pirvu EMAIL logo , Isabela Nicorescu , Cristina Hlevca , Bujor Albu and Valentin Nicorescu
From the journal Open Chemistry


Epilobium genus has been confirmed as an effective source of natural antimicrobials. However, the influence of Epilobi hirsuti herba derived products on usual antibiotics activity has not been studied. In this study, several standardized Epilobi hirsuti herba extracts (EHE) were evaluated in order to asses their potential effects on usual antibiotics tested on standard Gram-positive and Gram-negative bacterial strains in vitro. The results emphasized that the bacterial strains ranged from sensitive (MIC values between 50–200 μg GAE mL-1) (S. epidermidis ATCC 12228) to very resistant (E. coli strains), E. faecalis ATCC 29212 being practically immune to EHE. In terms of synergistic interaction, Tetracycline and Ampicillin combinations lead to the most important stimulatory effects, the diameters of the inhibition zone being even 60% bigger compared to the antibiotic alone. Synergistic effects between myricetin(galloyl) derivates and Tetracycline were also revealed on P. aeruginosa and E. coli strains. Together, it clearly demonstrated not only EHE’s own antimicrobial properties, but also their capacity to influence the antimicrobial potency of some common antibiotics. These results could be useful for the area of herbal medicines and as potential candidates in managing microbial resistance, but also for physicians and pharmacists using combined antibacterial therapy.

1 Introduction

Epilobium species (E. hirsutum, angustifolium, E. parviflorum, E. rosmarinifolium, E. spicatum, E. tetragonum) have been confirmed to have effective antimicrobial [1-3], anti-inflammatory [4-6] and analgesic [7] properties as well as with certain antiproliferative and cancer preventive effects on prostate tissue [8-11]. Furthermore, Epilobium species are described as nontoxic [6]. Epilobium species’ active phytocompounds are polyphenols such as ellagitannins, flavonoids (e.g., anthocianidins and miricetin and quercetin derivates) and gallic acid derivatives along with saponins, volatile oils and vitamins [12-14], essential amino acids (e.g., tyrosine, serine, threonine, cysteine, valine, serine, leucine and isoleucine, phenylalanine, proline) [15] and minerals (e.g., K, Mg. P, S, Cu, Co, Zn) [16].

Regarding the antimicrobial activity of Epilobium genus, studies [1] on a series of ethanolic extracts from E. angustifolium, E. hirsutum, E. palustre, E. tetragonum and E. rosmarinifolium supplied from (Boiron) France were tested on Gram-positive (Staphylococcus aureus two strains, Streptococcus pyogenes ATCC 12345, Streptococcus sanguis CDC SS 910, Bacillus subtilis ATCC 6633, Enterococcus faecalis, Listeria monocytogenes ATCC 19111) and Gram-negative (Escherichia coli ATCC 15221, Klebsiella pneumoniae ATCC 10031, Pseudomonas aeruginosa ATCC 7853, Shigella flexneri CDC 9767 IAL 1517 and Salmonella enteritidis IAL 1132) bacteria, yeasts (Candida albicans two strains, Candida glabrata two strains and Candida krusei) and fungi (Microsporum canis, Microsporum gypseum two strains, Tricophyton rubrum and Tricophyton mentagrophytes four strains) indicated that all extracts acted against studied bacteria in a range of concentrations measuring from 10 to 650 μg mL-1 dry extract; E. angustifolium and E. rosmarinifolium acted against yeasts and fungi as well.

Similarly, studies [2] on flowers and leaves of Epilobium angustifolium L. collected from Croatia (Mt. Velebit) that were tested on standard ATCC and clinical isolated Staphylococcus aureus (including MRSA), Bacillus subtilis, Escherichia coli (including p-fimbriae positive strain), Pseudomonas aeruginosa, Proteus mirabilis, Candida albicans, C. tropicalis, C. dubliniensis and Saccharomyces cerevisiae confirmed antimicrobial potency of both plant pieces and MIC values ranging from 4.6 ± 0.2 to 18.2 ± 0.8 mg mL-1. Our previous studies [14,17] on different whole and selective Epilobi hirsuti extracts using raw material (herba) from Romanian Carpathians highlighted the antimicrobial activity of the tested extracts against Staphylococcus aureus (standard ATTC and clinical isolated strains) and E. coli (standard ATTC strains).

Given the high therapeutic potential of Epilobium species, this work was aimed at evaluating potential interactions between some whole and selective, polar and non-polar, standardized Epilobi hirsuti herba extracts and several well known antibacterial drugs, and were tested on nine (standard) Gram-positive and Gram-negative bacteria.

This interest is motivated by current worldwide concern regarding the increasing phenomenon of bacterial resistance to antimicrobial drugs in parallel with more and more scientific proofs of the effectiveness of plant compounds in managing microbial infections. Therefore, the effect of cooperation between different plant compounds is well known, as well as that between plant compounds and chemical drugs leading to more complex biological benefits. The more so as there is ample literature data confirming additive and synergistic effects between plant compounds and susceptible antibiotics [18-20].

2 Experimental Procedure

2.1 Materials

2.1.1 Plant material description

Fresh mature aerial part (herba) of Epilobium hirsutum L. (Onagraceae family) was harvested in August from the wild, Romanian Carpathians respectively, at about 1000 m altitude (Sinaia region). The plant material was authenticated by the specialist’s of National Institute of Chemical-Pharmaceutical R&D (ICCF), Bucharest, Romania; specimen samples are deposited in ICCF Plant Material Storing Room (EH_AM2013-P8). Epilobi hirsuti herba raw material was shade dried and ground to a medium-size plant powder.

2.1.2 Vegetal extracts preparation

The plant powder was (twice) extracted in 70% (v/v) ethanol (500 mL) for 1 hour at 80−85°C. The extracts were mixed and filtered using paper filter Whatman No. 1 resulting in 850 ± 20 mL final ethanolic extract (codified E8).

The filtrate obtained with ethanol (250 mL E8) was concentrated to dryness under reduced pressure using a rotary evaporator (Büchi) and the resulting sicc product was passed into 20% (v/v) propylene glycol (PG) solution to provide the exactly 5 mg total phenols (expressed as gallic acid equivalents [GAE]) per 1 mL of extract/sample. The resulting standardized propylene glycol extract is further called great willowherb whole extract (codified P8).

Other 250 mL of filtrate obtained with ethanol (E8) were concentrated under reduced pressure and the final sicc product was solved into 100 mL of distilled water. The resulting aqueous solution was further (manually) extracted, first with (3 × 100 mL) chloroform and then with (3 × 100 mL) ethyl acetate, 24 hours for each stage of extraction. Aqueous and ethyl acetate fractions were (separately) concentrated at residue and the residues were passed into 20% PG so as to obtain the identical final concentration of 5 mg total phenols (GAE) per 1 mL of sample; the chloroform fraction was also concentrated at spiss product then passed into 20% PG by the whole extract (P8) algorithm, thus obtaining the equivalent of the whole extract (P8) as concerning the total non-polar compounds. Three standardized fractions resulted: the aqueous fraction (codified P8aq), ethyl acetate fraction (codified P8ea) and chloroform fraction (codified P8chl), further called Epilobi hirsuti herba selective extracts.

The whole extract (P8) as well as the three selective extracts (P8aq, P8ea and P8chl) were separately divided into 2 mL Eppendorf tubes and stored at -8°C until microbiological studies.

2.1.3 Chemicals, reagents and references

Reagents (Folin-Ciocalteau and Natural Product), solvents (methanol, ethanol, ethyl acetate, formic acid, acetic acid and chloroform) and reference compounds quercetin (95%), rutin (min. 95%), chlorogenic acid (>95%), caffeic acid (99%) and gallic acid (95%) were supplied by Sigma-Aldrich and Fluka (Bucharest, Romania).

2.2 Experimental Design

2.2.1 Qualitative (HP)TLC analysis

Studies were performed according to Wagner and Bladt’s [21] and Reich and Schibli’s [22], general method for polyphenols assessment, and detailed in our previous studies [14,17].

2.2.2 Estimation of Total Phenolics Content

Studies were performed according to a standard method described in Romanian Pharmacopoeia [23]. Briefly, three aliquots of 50−100 μL vegetal samples were mixed with 200 μL of Folin-Ciocalteau reagent and accurately finished at 5000 μL volumetric flasks with (5% w/v) sodium carbonate. Flasks were mixed shaken and left in the dark at room temperature for 5 minutes, and then the absorbance at maximum absorption wavelength (λ = 750 nm) measured. Gallic acid standard calibration curve (r2 = 0.9989) was used and the results were expressed as mg gallic acid and equivalent (GAE) per 1 mL of vegetal sample.

2.2.3 Antimicrobial Activity Assay

Test organisms: The tests were carried out on four Gram-positive bacteria, Staphylococcus aureus ATCC 6538, Staphylococcus aureus ATCC 25923, Enterococcus faecalis ATCC 29212, Staphylococcus epidermidis ATCC 12228 and five Gram-negative bacteria, Pseudomonas aeruginosa ATCC 27853, Proteus mirabilis ATCC 29245, Escherichia coli ATCC 35218, E. coli ATCC 11229, and E. coli ATCC 8739.

Test antimicrobials: Reference antibiotics (Biolab Zrt) included microtablets of Ampicillin (AM, 10 μg), Gentamicin (CN, 10 μg), Tetracycline (TE, 30 μg), Sulfamethoxazole/ Trimethoprim (SXT, 25 μg), Ciprofloxacin (CIP, 5 μg) and Cefoxitine (FOX, 30 μg).

Inoculum preparation: Nutrient broth (Oxoid CM0001) and Muller-Hinton agar (Oxoid CM0337) were used as culture media. Test microorganisms were stored in freezing conditions and activated by cultivation in Nutrient broth at 37°C for 24 hours. Overnight cultures were diluted with Mueller–Hinton broth until a turbidity equivalent to 0.5 McFarland standard was achieved (1−2 × 108CFU mL-1) [24]. The purity of the cultures was verified by streaking each culture on Nutrient agar supplemented with 5% sheep blood.

Minimum inhibitory concentration (MIC) assay: The experiments were conducted using the reference method for testing the in vitro activity of the antimicrobial agents [25] where MIC is the lowest concentration of an antimicrobial agent that, under defined in vitro conditions, prevents the appearance of visible growth of the microorganism after its incubation overnight [25,26]. The MIC assay was carried out using an accurate working scheme (Table 1) as follows: four dilution series were prepared, corresponding to the four vegetal extracts tested, the whole extract (P8) and the three selective extracts, aqueous (P8aq), ethyl acetate (P8ea) and chloroform (P8chl) fractions, each of them precisely quantified for total phenol content. The dilutions were made by incorporation of each vegetal extract into Muller-Hinton Agar (MHA); MHA + PG 20% (4.1 mL + 0.9 mL) were used as negative control. Total phenol concentrations in the resulting culture medium ranged in the 25–900 μg GAE mL-1 interval in the case of P8, P8aq and P8ea samples and between 1.25–45 μg GAE mL-1 in case of P8chl samples.

Table 1

Dilution series for MIC assay - working scheme.

E. hirsutum extract (mL)MHA (mL)Total phenols – P8, P8aq, P8ea extracts (μg GAE mL-1)Total phenols – P8chl extract (μg GAE mL-1)

After the solidification of MHA containing vegetal extracts, the bacterial inoculums (104 CFU/spot) were placed on the medium surface [27] and the plates were incubated for 24 hours at 37°C. The results were interpreted by evaluating the bacterial growth, depending on the vegetal extract concentration.

Synergism assay: In order to evaluate the potential synergistic effects between the four Epilobi hirsuti extracts and antibacterial substances tested, the vegetal extracts were incorporated in MHA in concentrations which did not by themselves inhibit the bacterial growth (MIC/2) [28]. Separately, plates with MHA without vegetal extract were prepared and used as controls. The dried surface of the culture medium was inoculated with bacterial suspension (1−2 × 108 UFC mL-1) by streaking with a sterile cotton swab and subsequently the antimicrobial micro-tablets were distributed. The plates were incubated for 24 hours at 37°C, and then the antimicrobial effect was evaluated by measuring the inhibition area around the micro-tablets.

Statistical analysis: All assays were conducted in triplicate and the values were expressed as mean ± (SD).

3 Results and Discussion

3.1 Qualitative and quantitative aspects of Epilobi hirsuti herba extracts

Similar to our previous study [14], Epilobi hirsuti herba whole extract (Fig. 1, T2 tracks) showed eight major polyphenolic compounds (s1 – s8 spots), myricetin (the five intense red-orange fluorescent zones represented of s2/s2’’, s3, s5, s6 and s7 spots) and myricetin-galloyl derivates (the two indigo fl. zones represented of s1 and s4 spots) as well as two phenolic acids, chlorogenic acid (blue fl. zone overlapped by myricetin derivate – s2/s2’ spot) and gallic acid aglycone (dark blue fl. zone – s8 spot).

Epilobi hirsuti herba selective extracts (Fig. 1, T2aq, Tea and T2chl tracks) revealed the following qualitative aspects: the aqueous fraction (T2aq tracks) showed two major phenolics, chlorogenic acid (s2’) and one kaempferol derivate (s2’’’); the ethyl acetate fraction (T2ea tracks) showed myricetin and myricetin-galloyl derivates; the chloroform fraction (T2chl track) did not reveal the type of polyphenols compounds.

Figure 1 Qualitative (HPTLC) analytical aspects of Epilobi hirsuti herba whole and selective extracts. Track T1, rutin, chlorogenic acid and caffeic acid (ref.); Tracks T2, great willowherb whole extract (duplicate); Tracks T2aq, selective aqueous extract (duplicate); Tracks T2ea, selective ethyl acetate extract (duplicate); Track T2chl, selective chloroform extract (single sample).
Figure 1

Qualitative (HPTLC) analytical aspects of Epilobi hirsuti herba whole and selective extracts. Track T1, rutin, chlorogenic acid and caffeic acid (ref.); Tracks T2, great willowherb whole extract (duplicate); Tracks T2aq, selective aqueous extract (duplicate); Tracks T2ea, selective ethyl acetate extract (duplicate); Track T2chl, selective chloroform extract (single sample).

With regards to quantitative aspects, Epilobi hirsuti herba polar extracts including the whole extract (P8) as well as the two selective extracts, aqueous (P8 aq) and ethyl acetate (P8ea) fractions were made so as to assure identical total phenols content, 5 mg GAE mL-1 sample. As for the selective, non-polar, chloroform (P8chl) fraction, although chloroform is not a solvent in which polyphenols are typically soluble and extracted, our laboratory practice has revealed that chloroform extracts often contain small amounts of polyphenol compounds. In the particular case of Epilobi hirsuti herba extracts, the chloroform fraction (P8chl) showed 0.25 mg total phenols (GAE) mL-1 extract.

Therefore, the four Epilobi hirsuti herba extracts (EHE) differed in terms of qualitative content, but were identical in terms of quantitative content and the chloroform fraction was designed to provide the same amount of non-polar compounds as the whole extract does. This allows further assessments of Epilobi hirsuti herba polar and non-polar compounds’ contribution to antimicrobial activity and synergistic effects in combination with usual antibiotics on standard Gram-positive and Gram-negative microbial strains.

3.2 Evaluation of the minimum inhibitory concentration (MIC)

Foremost it must be noted that during the tests, the nine bacterial strains properly developed on MHA and MHA + PG culture medium, thus demonstrating the lack of influence of propylene glycol solution (PG 20%, v/v) on bacterial growth. MIC values of the four Epilobi hirsuti herba extracts tested on the (nine) bacterial strains are shown in Table 2.

Table 2

MIC values of Epilobi hirsuti herba extracts tested on ATCC bacterial strains.

NoBacterial strainMIC (μg GAE mL-1)
Whole Selective extracts
1Staphylococcus aureus

ATCC 6538
2Staphylococcus aureus

ATCC 25923
3Enterococcus faecalis

ATCC 29212
> 900> 900> 900> 45
4Pseudomonas aeruginosa

ATCC 27853
5Proteus mirabilis

ATCC 29245
6Staphylococcus epidermidis

ATCC 12228
7Escherichia coli

ATCC 35218
700900> 900>45
8Escherichia coli

ATCC 11229
9Escherichia coli

ATCC 8739

The results (Table 2) indicated good antimicrobial activity of the three polar, polyphenolic extracts (whole/P8, aqueous/P8aq and ethyl acetate/P8ea extracts), which were effective on five microbial strains, S. epidermidis ATCC 12228, P. mirabilis ATCC 29245, P. aeruginosa ATCC 27853, S. aureus ATCC 25923 and S. aureus ATCC 6538 respectively; MIC values ranged between 50 - 350 μg GAE mL-1. Also, it clearly revealed the lack of activity of Epilobi hirsuti extracts on E. faecalis ATCC 29212 and the three E. coli strains (MIC > 500 μg GAE mL-1). The chloroform fraction (P8chl) proved to be effective mainly on S. epidermidis ATCC 12228 and, in a smaller extent, on S. aureus ATCC 25923. On the other seven microbial strains, the P8chl extract was basically ineffective.

3.3 Evaluation of the synergistic effects upon several usual antibiotics

Studies included six common antibiotics massively used for treating infections worldwide; their continuously increasing susceptibility to bacterial resistance is confirmed by official reports of the European Union [29]). Furthermore, each selected substance for the assay belongs to a separate class of antibacterials as follows: Penicillins (Ampicillin/AM), Aminoglycosides (Gentamicin/CN), Tetracyclines (Tetracycline/TE), Potentiated Sulphonamides (Sulfamethoxazole-Trimethoprim/SXT), Fluoroquinolones (Ciprofloxacin/ CIP), and Cephalosporins (Cefoxitine/FOX).

As the working principles, for those bacterial strains whose MIC values could not be determined (e.g., E. faecalis ATCC 29212) the synergism tests were not performed. For bacteria (e.g., S. epidermidis ATCC 12228) or fractions (e.g. P8chl) that showed MIC values lower than 200 μg GAE mL-1 (high-susceptible) or higher than 900 μg GAE mL-1 (low-susceptible), the synergism tests were not performed either; these samples are pointed out as ND (not determined). Significant synergy (stimulator effect) between the antimicrobial substances and Epilobi hirsuti herba extracts was considered when the enlargement of the combined inhibition zone of at least 5 mm was recorded [30]. The results are presented in Table 3.

Table 3

Synergistic effects of Epilobi hirsuti herba extracts and antimicrobials on standard microbial strains.

Composition of culture mediumMicrobial strain / Diameter of the inhibition zone (mm) ± SD
S. aureus 6538S. aureus 25923P. aeruginosa 27853P. mirabilis 29245E. coli 35218E. coli 11229E. coli 8739
TE combinations
MHA+PG (reference)32 ± 1.0032 ± 1.3218 ± 2.646 ± 0.0025 ± 1.3224 ± 0.8624 ± 1.00
MHA+P832 ± 0.8632 ± 1.7324 ± 1.73ND30 ± 1.3228 ± 1.0029 ± 1.32
MHA+P8aq38 ± 1.32ND22 ± 1.00NDND33 ± 1.8032 ± 1.00
MHA+P8ea33 ± 1.73ND28 ± 1.73ND34 ± 1.8028 ± 1.7331 ± 1.80
MHA+P8chl40 ± 1.8039 ± 0.5021 ± 1.328 ± 1.00NDNDND
AM combinations
MHA+PG (reference)44 ± 1.3231 ± 0.866 ± 0.0019 ± 1.736 ± 0.0013 ± 0.5015 ± 1.73
MHA+P843 ± 1.0032 ± 1.326 ± 0.00ND6 ± 0.0018 ± 1.7318 ± 0.5
MHA+P8aq43 ± 1.73ND6 ± 0.00NDND18 ± 1.0019 ± 1.00
MHA+P8ea40 ± 1.32ND6 ± 0.00ND6 ± 0.0021 ± 1.0019 ± 0.86
MHA+P8chl46 ± 1.7336 ± 1.736 ± 0.0024 ± 1.80NDNDND
CIP combinations
MHA+PG (reference)33 ± 1.0033 ± 0.536 ± 2.0242 ± 1.8035 ± 1.7333 ± 2.5933 ± 1.00
MHA+P835 ± 1.7333 ± 0.8641 ± 1.73ND36 ± 1.7334 ± 1.0040 ± 1.00
MHA+P8aq36 ± 1.73ND40 ± 1.32NDND36 ± 0.8636 ± 1.73
MHA+P8ea34 ± 0.86ND44 ± 2.64ND37 ± 2.6436 ± 1.7336 ± 1.00
MHA+P8chl44 ± 0.8638 ± 0.8642 ± 1.7340 ± 1.32NDNDND
CN combinations
MHA+PG (reference)24 ± 0.5025 ± 0.5030 ± 0.8622 ± 1.5020 ± 1.7321 ± 0.8621 ± 1.32
MHA+P826 ± 1.7326 ± 1.5028 ± 1.32ND17 ± 1.7319 ± 1.5020 ± 1.00
MHA+P8aq26 ± 1.00ND30 ± 1.00NDND23 ± 0,5020 ± 0.50
MHA+P8ea24 ± 0.50ND32 ± 1.00ND20 ± 1.0019 ± 2.2921 ± 1.00
MHA+P8chl26 ± 1.3225 ± 0.531 ± 1.7322 ± 1.00NDNDND
SXT combinations
MHA+PG (reference)26 ± 1.3229 ± 1.326 ± 0.0029 ± 1.3222 ± 0.8626 ± 0.8628 ± 1.73
MHA+P826 ± 1.7331 ± 1.736 ± 0.00ND21 ± 0.8628 ± 1.7332 ± 1.73
MHA+P8aq34 ± 1.73ND6 ± 0.00NDND37 ± 0.5036 ± 2.17
MHA+P8ea26 ± 1.32ND6 ± 0.00ND22 ± 1.8030 ± 1.8034 ± 1.32
MHA+P8chl32 ± 0.8630 ± 1.806 ± 0.0034 ± 1.32NDNDND
FOX combinations
MHA+PG (reference)29 ± 0.5031 ± 1.326 ± 0.0021 ± 1.8026 ± 2.1724 ± 1.0025 ± 1.32
MHA+P829 ± 1.7332 ± 1.006 ± 0.00ND24 ± 0.8626 ± 0.8629 ± 1.73
MHA+P8aq30 ± 1.32ND6 ± 0.00NDND25 ± 1.0030 ± 1.00
MHA+P8ea30 ± 1.32ND6 ± 0.00ND26 ± 1.0025 ± 1.3230 ± 1.32
MHA+P8chl38 ± 1.0036 ± 0.866 ± 0.0023 ± 1.00NDNDND

Where: ND = Not determined

Figs. 27 illustrate bacterial response after the treatment with respective vegetal-chemical antimicrobial combination (Epilobi hirsuti herba whole or selective extract plus antibiotic), stimulator response compared to the reference sample, relative ratio (%) respectively.

Figure 2 TE combinations.
Figure 2

TE combinations.

Figure 3 AM combinations.
Figure 3

AM combinations.

Figure 4 CIP combinations.
Figure 4

CIP combinations.

Figure 5 CN combinations.
Figure 5

CN combinations.

Figure 6 SXT combinations.
Figure 6

SXT combinations.

Figure 7 FOX combinations.
Figure 7

FOX combinations.

As can be seen in Fig. 2, the Tetracycline (TE) antibiotic acted much more effectively with whole and selective Epilobi hirsuti extracts on all tested strains, mainly on P. aeruginosa ATCC 27853 when combined with the ethyl acetate (P8ea) fraction previously shown as containning myricetin and myricetin-galloyl derivates; TE efficiency also increased on E. coli strains by combining with Epilobi hirsuti polar extracts, whole extract (P8), aqueous (P8eq) and ethyl acetate (P8ea) fractions respectively, as well as on S. aureus strains when combined with non-polar, chloroform (P8chl) fraction; TE and chloroform (P8chl) fraction also resulted in a increase of efficacy on P. mirabilis ATCC 29145.

Ampicillin (AM) antibiotic (Fig. 3) also acted more effective on two of the three E. coli strains when combined with Epilobi hirsuti polar extracts (P8, P8aq and Pea). Similar to TE, AM gained efficacy against S. aureus ATCC 25923 and P. mirabilis ATCC 29145, when combined with the non-polar, chloroform (P8chl) fraction.

Ciprofloxacin (CIP) indicated (Fig. 4) an increase of efficiency on S. aureus strains when combined with the chloroform (P8chl) fraction, as well as on P. aeruginosa ATCC 27853 by combining with all Epilobi hirsuti extracts, but especially with selective ethyl acetate (P8ea) fraction.

Gentamicin (CN) in combination with tested extracts (Fig. 5) indicated weak stimulatory effects and only on S. aureus ATCC 6538, E. coli ATCC 11229 and P. aeruginosa ATCC 27853.

Sulfamethoxazole/Trimethoprim (SXT) combinations with polar extracts (Fig. 6) indicated an increase of efficiency on two of the three E. coli strains, mainly the aqueous (P8ea) fraction previously shown as containing two phenolics, chlorogenic acid and kaempferol glycoside.

Cefoxitine (FOX) combinations (Fig. 7) lead to weak to moderate stimulatory effects on S. aureus and E. coli strains also by combining with non-polar and, respectively, polar extracts. SXT and FOX antibiotics, both of them gained efficacy against P. mirabilis ATCC 29245 by combining with non-polar, chloroform (P8chl) fraction.

In terms of the bacterial sensitivity (Figs. 814), for S. aureus ATCC 6538 (Fig. 8), the most significant synergistic effects were recorded for the combination of the non-polar, chloroform fraction (P8chl) with CIP, FOX, TE and SXT. Compared to reference sample (MHA + PG), there were obtained rises of inhibition zones measuring from 6 to 11 mm, meaning 19 to 33% stimulatory effects.

Figure 8 S. aureus ATCC 6538 response.
Figure 8

S. aureus ATCC 6538 response.

Figure 9 S. aureus ATCC 25923 response.
Figure 9

S. aureus ATCC 25923 response.

Figure 10 P. aeruginosa ATCC 27853 response.
Figure 10

P. aeruginosa ATCC 27853 response.

Figure 11 P. mirabilis ATCC 29245 response.
Figure 11

P. mirabilis ATCC 29245 response.

Figure 12 E. coli ATCC 35218 response.
Figure 12

E. coli ATCC 35218 response.

Figure 13 E. coli ATCC 11229 response.
Figure 13

E. coli ATCC 11229 response.

Figure 14 E. coli ATCC 8739 response.
Figure 14

E. coli ATCC 8739 response.

For S. aureus ATCC 25923 (Fig. 9), there were synergistic interactions for the combination of the non-polar, chloroform (P8chl) fraction with TE, AM, FOX and CIP, the diameter of the inhibition zone increasing by 5 to 7 mm, quantified as 15 to 22% stimulatory effects.

P. aeruginosa ATCC 27853 (Fig. 10) indicated high sensitivity to TE and CIP combinations with all Epilobi hirsuti herba extracts, but especially with the selective, ethyl acetate (P8ea) fraction, leading to increases of the diameter of the inhibition zone by 22% (in case of CIP) and by 55% (in case of TE), compared to reference sample.

P. mirabilis ATCC 29245 (Fig. 11) showed an increase of sensitivity by combining TE, AM, SXT and FOX with the Epilobi hirsuti non-polar fraction (P8chl) resulting in the increase of the inhibition zones from 17 to 26%, also compared to reference sample.

In case of the E. coli ATCC 35218 strain (Fig. 12), a synergistic activity between TE and two polar extracts, the whole extract (P8) and selective ethyl acetate (P8ea) fraction has been noticed; the diameter of the inhibition zone, antimicrobial effect respectively, increased by 20 to 36%.

E. coli ATCC 11229 strain (Fig. 13) significantly reacted when combined AM with Epilobi hirsuti polar extracts; the whole extract P8 (by 38%), the selective aqueous P8aq fraction (by 38%) and ethyl acetate P8ea (by 61%) fraction. Synergistic effects were also recorded by combining the aqueous P8aq fraction with TE (by 37%) and SXT (by 42%) antibiotics. E. coli ATCC 8739 strain (Fig. 14) reacted when TE was combined with Epilobi hirsuti herba polar extracts; the whole extract (P8) lead to the increase of the inhibition zone by 21%, the selective aqueous (P8aq) fraction by 33% and ethyl acetate (P8ea) fraction by 29%. Significant increases of the inhibition zone diameters were highlighted for the combination of the selective aqueous (P8aq) fraction and selective ethyl acetate (P8ea) fraction with SXT (by 28% and 21%, respectively) and FOX (by 20% for both fractions) as well as by combining Epilobi hirsuti herba whole extract (P8) with CIP (by 21%), all compared to reference sample.

Collectively, our results suggest synergistic effects between myricetin and/or myricetin-galloyl derivates and Tetracycline, on P. aeruginosa and E. coli strains. Similarly, an increased efficacy of Amoxicillin, Ampicillin and Cefoxitine in combination with myricetin has been previously reported [20].

4 Conclusions

Epilobim hirsutum L. is a valuable phytomedicine worldwide renowned for its benefits on skin and prostate tissues thus resulting in numerous plant derived products, herbal medicines, cosmetics and hygiene products as well. The most frequent commercial applications of Epilobium sp. refer to topical curative (anti-irritant, anti-inflammatory and anti-oxidant) products. As for internal use, the extracts from Epilobium sp. can be found as different formulations (capsules, softgel capsules), single or in combination with other plant-derived products, primarily for prostate treatment. Romanian folk medicine and corresponding commercial products recommend Epilobi hirsuti plant derived products for treating urinary, liver, gastric and intestinal disorders too. Given the high interest for Epilobi hirsuti plant derived products in managing urinary, but also various digestive system disorders, studying Epilobi hirsuti herba extracts capacity to influence the in vitro activity of some usual antibiotics is of high importance.

In this way, our studies indicated that, in terms of the susceptibility to Epilobi hirsuti herba extracts (EHE), the nine bacterial strains ranged from sensitive (S. epidermidis ATCC 12228) to very resistant (E. coli strains), E. faecalis ATCC 29212 being practically immune to Epilobium active compounds. Thus, if the polar extracts, including whole extract (P8), and aqueous (P8aq) and ethyl acetate (P8ea) fractions were very effective on S. epidermidis ATCC 12228, P. mirabilis ATCC 29245, P. aeruginosa ATCC 27853 and S. aureus ATCC 25923 strains (MIC values from 50 to 200 μg GAE mL-1 sample), the non-polar, chloroform (P8chl) fraction, was effective mainly on S. epidermidis ATCC 12228.

In terms of the synergistic interaction with some common antimicrobials (antibiotics), Tetracycline (TE) established the biggest number of interactions (eleven) and with all tested Epilobi hirsuti herba whole and selective extracts, this property being highlighted by the enlargement of the inhibition zones diameter by 19 to 55% compared to the antibiotic alone. Comparatively, Ciprofloxacin (CIP) established six synergistic interactions with all tested extracts with the exception of selective aqueous fractions, their intensity ranging from 14% to 33% compared to the antibiotic alone. Sulfamethoxazole/Trimethoprim (SXT) established six synergistic interactions with selective fractions only, their intensity ranging from 17% to 42%. Ampicillin (AM) established five synergistic interactions with all Epilobi hirsuti herba whole and selective extracts, their intensity ranging from 16% to 61%. Cefoxitine (FOX) established four synergistic interactions with selective fractions only, their intensity ranging from 16% to 31%, while Gentamicin (CN) revealed only weak stimulator effects in combination with both, polar and non-polar Epilobi hirsuti herba extracts.

Together, these results demonstrate not only Epilobi hirsuti herba extracts own antimicrobial properties, but also the capacity to influence the antimicrobial potency of some common antibiotics.

These results could be useful for the area of herbal medicines and as potential candidates in managing microbial resistance, but also for physicians and pharmacists using combined antibacterial therapy.

Lucia Pirvu: National Institute for Chemical-Pharmaceutical Research and Development (ICCF), Vitan 112, 031299, Bucharest, Romania


[1] Battinelli L., Tita B., Evandri M.G., Mazzanti G., Antimicrobial activity of Epilobium spp. Extracts, Farmaco, 2001, 56, 345-8.10.1016/S0014-827X(01)01047-3Search in Google Scholar

[2] Kosalec I., Kopjar I., Kremer D., Antimicrobial activity of Willowherb (Epilobium angustifolium L.) leaves and flowers, Curr Drug Targets, 2013, 14, 986-91.10.2174/13894501113149990177Search in Google Scholar PubMed

[3] Silló S., Varga E., Belák Á., Maráz A., Phytochemical and antimicrobial investigation of Epilobium angustifolium L, Acta Pharm Hung., 2014, 84, 105-10.Search in Google Scholar

[4] Hevesi Tóth B., Blazics B., Kéry A., Polyphenol composition and antioxidant capacity of Epilobium species, Journal of pharmaceutical and biomedical analysis, 2009, 49, 26-31.10.1016/j.jpba.2008.09.047Search in Google Scholar PubMed

[5] Kiss AK., Bazylko A., Filipek A., Granica S., Jaszewska E., Kiarszys U., Kośmider A., Piwowarski J., Oenothein B’s contribution to the anti-inflammatory and antioxidant activity of Epilobium sp., Phytomedicine: international journal of phytotherapy and phytopharmacology, 2011, 18, 557-60.10.1016/j.phymed.2010.10.016Search in Google Scholar PubMed

[6] Granica Sx., Piwowarski JP., Czerwińska ME., Kiss AK., Phytochemistry, pharmacology and traditional uses of different Epilobium species (Onagraceae): A review, Journal of ethnopharmacology, DOI: 10.1016/j.jep.2014. in Google Scholar

[7] Pourmorad F., Ebrahimzadeh M.A., Mahmoudi M., Yasini S., Antinociceptive activity of methanolic extract of Epilobium hirsutum, Pak J Biol Sci., 2007, 10, 2764-7.10.3923/pjbs.2007.2764.2767Search in Google Scholar PubMed

[8] Kiss A., Kowalski J., Melzig MF., Compounds from Epilobium angustifolium inhibit the specific metallopeptidases ACE, NEP and APN, Planta medica, 2004, 70, 919-23.10.1055/s-2004-832617Search in Google Scholar PubMed

[9] Vitalone A., McColl J., Thome D., Costa LG., Tita B., Characterization of the effect of Epilobium extracts on human cell proliferation, Pharmacology, 2003, 69, 79-87.10.1159/000072360Search in Google Scholar PubMed

[10] Stolarczyk M., Piwowarski JP., Granica S., Stefańska J., Naruszewicz M., Kiss AK., Extracts from Epilobium sp. herbs, their components and gut microbiota metabolites of Epilobium ellagitannins, urolithins, inhibit hormone-dependent prostate cancer cells-(LNCaP) proliferation and PSA secretion, Phytotherapy research, 2013, 27, 1842-8.10.1002/ptr.4941Search in Google Scholar PubMed

[11] Stolarczyk M., Naruszewicz M., Kiss AK., Extracts from Epilobium sp. herbs induce apoptosis in human hormone-dependent prostate cancer cells by activating the mitochondrial pathway, The Journal of pharmacy and pharmacology, 2013, 65, 1044-54.10.1111/jphp.12063Search in Google Scholar PubMed

[12] Barakat H., Sahar Hussein A.M., Marzouk S.M., Merfort I., Linscheid M.A., Mahmoud Nawwar A.M., Polyphenolic metabolites of Epilobium hirsutum, Phytochemistry, 1997, 46, 935-941.10.1016/S0031-9422(97)00370-1Search in Google Scholar

[13] Bazylko A., Kiss AK., Kowalski J., High-performance thin-layer chromatography method for quantitative determination of oenothein B and quercetin glucuronide in aqueous extract of Epilobii angustifolii herba, Journal of chromatography, 2007, 1173, 146-50.10.1016/j.chroma.2007.10.019Search in Google Scholar PubMed

[14] Pirvu L., Hlevca C., Nicu I., Bubueanu C., Comparative Analytical, Antioxidant and Antimicrobial Activity Studies on a Series of Vegetal Extracts Prepared from Eight Plant Species Growing in Romania, JPC. Journal of Planar Chromatography, 2014, 27, 346-356.10.1556/JPC.27.2014.5.4Search in Google Scholar

[15] Ludovic E.B., Neli O., George D.M., Cornelia B., Johny N., Honorius P., Researches upon the free amino acids serine and threonine in five Epilobium species (Onagraceae), Farmacia, 2009, 57, 192-200.Search in Google Scholar

[16] Parvu C. – Plant Encyclopaedia (in Romanian), Tehnica, Bucuresti, 2005.Search in Google Scholar

[17] Pirvu L., Nicorescu V., Hlevca C., Udeanu I.D., Nicorescu I., Antimicrobial and synergistic activity of some whole and selective Epilobium hyrsutum L. (great willowherb) extracts tested on standard and wild S. aureus strains, Farmacia, 2015, 63, 690-695.Search in Google Scholar

[18] Chanda S., Rakholiya K., Science against microbial pathogens: communicating current research and technological advances. A. Mendez-Vilas (Ed.) Formatex Research Center, 2011.Search in Google Scholar

[19] Mabrouk M.I., Synergistic and Antibacterial Activity of SIX Medicinal Plants Used In Folklore Medicine In Egypt Against E. coli O157: H7, Journal of Applied Sciences Research, 2012, 8, 1321-1327.Search in Google Scholar

[20] Hemaiswarya S., Kruthiventi A.K., Doble M., Synergism between natural products and antibiotics against infectious diseases, Phytomedicine, 2008, 15, 639-652.10.1016/j.phymed.2008.06.008Search in Google Scholar PubMed

[21] Wagner H., Bladt S., Plant Drug Analysis. A Thin Layer Chromatography Atlas (2nd edn). Springer–Verlag: Berlin Heidelberg, 1996.10.1007/978-3-642-00574-9Search in Google Scholar

[22] Reikh E., Schibli A., HPTLC for the Analysis of Medicinal Plants. Thieme, N.Y.-Stuttgart, 2008.10.1055/b-0034-65242Search in Google Scholar

[23] Romanian Pharmacopoeia, Xth ed., Medicala, Bucharest, 1993.Search in Google Scholar

[24] Lakis Z., Mihele D., Nicorescu I., Vulturescu V., Udeanu I.D., The antimicrobial activity of Thymus vulgaris and Origanum syriacum essential oils in Staphylococcus aureus, Streptococcus pneumoniae and Candida albicans, Farmacia, 2012, 6, 857-865.Search in Google Scholar

[25] ISO 20776-1/2006. Clinical laboratory testing and in vitro diagnostic test systems – Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices – Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. International Organization for Standardization, Geneva, Switzerland, 2006.Search in Google Scholar

[26] CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard - 9th Edition. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory Standards Institute, 32(2), 2012.Search in Google Scholar

[27] Andrews J.M., Determination of minimum inhibitory concentrations, Journal of Antimicrobial Chemotherapy, 2001, 48, 5-16.10.1093/jac/48.suppl_1.5Search in Google Scholar PubMed

[28] Noumedem J.A.K., Mihasan M., Kuiate J.R., Stefan M., Cojocaru D., Dzoyem J.P., Kuete V., In vitro antibacterial and antibiotic-potentiation activities of four edible plants against multidrug-resistant gram-negative species, BMC Complementary and Alternative Medicine, 2013, 13, 190-199.10.1186/1472-6882-13-190Search in Google Scholar PubMed PubMed Central

[29] European Food Safety Authority (EFSA) & European Centre for Disease Prevention and Control (ECDC), EU Summary Report on antimicrobial resistance in zoonotic and indicator bacteria from humans, animals and food in 2013, EFSA Journal, 2015,13, 4036.10.2903/j.efsa.2015.4036Search in Google Scholar

[30] Ahmad I., Aqil F., In vitro efficacy of bioactive extracts of 15 medicinal plants against ESbL producing multidrug-resistant enteric bacteria, Microbiological Research, 2007, 162, 264-275.10.1016/j.micres.2006.06.010Search in Google Scholar PubMed

Received: 2015-11-2
Accepted: 2016-1-26
Published Online: 2016-3-30
Published in Print: 2016-1-1

© A. Heidari Dahooei et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Downloaded on 5.6.2023 from
Scroll to top button